Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up

被引：48

作者：

Dimakakos, Andreas ^{[1
]}

Armakolas, Athanasios ^{[1
]}

Koutsilieris, Michael ^{[1
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Sch Med, Physiol Lab, Athens 11527, Greece

来源：

BIOMED RESEARCH INTERNATIONAL | 2014年 / 2014卷

关键词：

CIRCULATING TUMOR-CELLS; FACTOR-I RECEPTOR; MESENCHYMAL TRANSITION EMT; ANTIGEN MESSENGER-RNA; GROWTH-FACTOR; MEMBRANE ANTIGEN; PLASMINOGEN-ACTIVATOR; IGF1R INHIBITION; IMMUNE-RESPONSE; BONE METASTASIS;

D O I：

10.1155/2014/890697

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Prostate-specific antigen (PSA) is the main diagnostic tool when it comes to prostate cancer but it possesses serious limitations. Therefore, there is an urgent need for more sensitive and specific biomarkers for prostate cancer prognosis and patient follow-up. Recent advances led to the discovery of many novel diagnostic/prognostic techniques and provided us with many worthwhile candidates. This paper briefly reviews the most promising biomarkers with respect to their implementation in screening, early detection, diagnostic confirmation, prognosis, and prediction of therapeutic response or monitoring disease and recurrence; and their use as possible therapeutic targets. This review also examines the possible future directions in the field of prostate cancer marker research.

引用

页数：9

共 121 条

[1] Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma [J].

Abraham, Jinu ;

Prajapati, Suresh I. ;

Nishijo, Koichi ;

Schaffer, Beverly S. ;

Taniguchi, Eri ;

Kilcoyne, Aoife ;

McCleish, Amanda T. ;

Nelon, Laura D. ;

Giles, Francis G. ;

Efstratiadis, Argiris ;

LeGallo, Robin D. ;

Nowak, Brent M. ;

Rubin, Brian P. ;

Malempati, Suman ;

Keller, Charles .

MOLECULAR CANCER THERAPEUTICS, 2011, 10 (04) :697-707

[2]

Amaro A., 2014, CANC METASTASIS REV

[3] PSA screening and prostate cancer risk reduction [J].

Andriole, Gerry L., Jr. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (06) :936-937

[4]

Anose BM, 2008, ADV EXP MED BIOL, V617, P541, DOI 10.1007/978-0-387-69080-3_55

[5] Targeting the insulin-like growth factor-1 receptor in human cancer [J].

Arcaro, Alexandre .

FRONTIERS IN PHARMACOLOGY, 2013, 4

[6] Detection of the circulating tumor cells in cancer patients [J].

Armakolas, Athanasios ;

Panteleakou, Zacharoula ;

Nezos, Adrianos ;

Tsouma, Aikaterini ;

Skondra, Maria ;

Lembessis, Peter ;

Pissimissis, Nikolaos ;

Koutsilieris, Michael .

FUTURE ONCOLOGY, 2010, 6 (12) :1849-1856

[7] Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers [J].

Armstrong, Andrew J. ;

Marengo, Matthew S. ;

Oltean, Sebastian ;

Kemeny, Gabor ;

Bitting, Rhonda L. ;

Turnbull, James D. ;

Herold, Christina I. ;

Marcom, Paul K. ;

George, Daniel J. ;

Garcia-Blanco, Mariano A. .

MOLECULAR CANCER RESEARCH, 2011, 9 (08) :997-1007

[8] International epidemiology of prostate cancer: Geographical distribution and secular trends [J].

Baade, Peter D. ;

Youlden, Danny R. ;

Krnjacki, Lauren J. .

MOLECULAR NUTRITION & FOOD RESEARCH, 2009, 53 (02) :171-184

[9] Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer [J].

Barnett, Christine M. ;

Heinrich, Michael C. ;

Lim, Jeong ;

Nelson, Dylan ;

Beadling, Carol ;

Warrick, Andrea ;

Neff, Tanaya ;

Higano, Celestia S. ;

Garzotto, Mark ;

Qian, David ;

Corless, Christopher L. ;

Thomas, George V. ;

Beer, Tomasz M. .

CLINICAL CANCER RESEARCH, 2014, 20 (05) :1306-1312

[10] Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia [J].

Barry, MJ .

UROLOGY, 2001, 58 (6A) :25-32

← 1 2 3 4 5 6 7 8 9 10 →